Doxazosin Tablet
Product Images NDC 51655-476

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 51655-476). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 476 52)

Label (51655 476 52)
NDC 51655-476-52 is an Rx only medication of Doxazosin Mesylate. This medication comes in tablets form with a concentration of 1mg. Please refer to the package insert for dosage information. The medication needs to be stored at 20°-25°C (68'-77°F), and it can be allowed to be in the temperature range between 15°-30°C (59°-86°F). The packaging of the medication should be kept away from children. The tablets should always be in the original container. The lot is 0000000000, and it has been repackaged by Northwind Pharmac in Indianapolis, IN 46203. The GTIN number is 0, serial number is 000000000000000, EXP is 00/, and the lot is 0000000000.*
FDA Label Image

Doxazosin-structure.jpg (Doxazosin Structure)

FDA Label Image

Figure1.jpg (Figure1)

FDA Label Image

Table3.jpg (Table3)

Table3.jpg (Table3)
This is a table summarizing the effectiveness of doxazosin in placebo-controlled trials for treating benign prostatic hyperplasia (BPH). The table shows the maximum flow rate, symptom score, and rate of change for patients who received doxazosin and those who received a placebo. The studies had different titration methods and durations. The effectiveness was assessed using the AUA questionnaire and the Modified Boyarsky Questionnaire. The table also provides details on the number of patients in each study, baseline measurements, and changes to the endpoint or fixed-dose efficacy phase.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.